Volume 3, Issue 1, Pages 1-9 (January 2017)

Slides:

Advertisements

Similar presentations

2015 Alzheimer's disease facts and figures Alzheimer's & Dementia: The Journal of the Alzheimer's Association Volume 11, Issue 3, Pages (March.

Advertisements

EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep

Sleep disruption changes across the disease trajectory: Pilot findings from the healthy patterns sleep study Nancy A. Hodgson, Albert J. Safi Alzheimer's.

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Middle age self-report risk score predicts cognitive functioning and dementia in 20– 40 years Eero Vuoksimaa, Juha O. Rinne, Noora Lindgren, Kauko Heikkilä,

Volume 1, Issue 1, Pages (June 2015)

Volume 3, Issue 4, Pages (November 2017)

Volume 3, Issue 1, Pages (January 2017)

Cerebrospinal fluid biomarkers for Alzheimer's disease are associated with neuropathology in cortical brain biopsy Toni Seppälä, Ossi Nerg, Anne Koivisto,

Correlations between amyloid and metabolic pet imaging in cognitively normal adults with a family history of late-onset Alzheimer's disease Megan Cummings,

[11C]PIB-, [18F]FDG-PET and MRI imaging in patients with Parkinson’s disease with and without dementia Pekka Jokinen, Noora M. Scheinin, Sargo Aalto,

Alzheimer's & Dementia: The Journal of the Alzheimer's Association

Volume 1, Issue 3, Pages (November 2015)

NICHOLAS J. TALLEY, M.B., Ph.D., SIDNEY F. PHILLIPS, M.D.

Volume 3, Issue 3, Pages (September 2017)

Longitudinal evaluation of criteria for subjective cognitive decline and preclinical Alzheimer's disease in a memory clinic sample Marie Eckerström,

Volume 1, Issue 1, Pages (June 2015)

Volume 3, Issue 2, Pages (June 2017)

Detecting functional decline from normal aging to dementia: Development and validation of a short version of the Amsterdam IADL Questionnaire Roos J.

Volume 3, Issue 2, Pages (June 2017)

Alzheimer's disease drug development pipeline: 2017

Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review Christian Thoma, Christopher P. Day, Michael.

An amylin analog used as a challenge test for Alzheimer's disease

Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline Sander C.J.

Volume 2, Issue 1, Pages (January 2016)

Volume 3, Issue 1, Pages (January 2017)

Ben Sherwood, Andrew Xiao-Hua Zhou, Sandra Weintraub, Lan Wang

L. Boyanova Clinical Microbiology and Infection

Alzheimer's disease drug development pipeline: 2018

American Journal of Kidney Diseases

Brain Injury Coping Skills Group: A Preventative Intervention for Patients With Brain Injury and Their Caregivers Samantha L. Backhaus, PhD, Summer L.

Osteoarthritis year 2010 in review: pharmacological therapies

Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma

Volume 154, Issue 1, Pages e6 (January 2018)

R. Cantón Clinical Microbiology and Infection

S. Imindu Liyanage, Clarissa Santos, Donald F. Weaver

Martin R. Farlow, MD Mayo Clinic Proceedings

Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance

Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized,

Trends in antibiotic prescribing in general internal medicine wards: antibiotic use and indication for prescription B. Maraha, M. Bonten, H. Fiolet,

Cognitive enhancement by drugs in health and disease

John Widger, Sarath Ranganathan, Philip J. Robinson

CMI editorial report 2011 Clinical Microbiology and Infection

Equivalence of a single dose (1200 mg) compared to a three-time a day dose (400 mg) of chondroitin 4&6 sulfate in patients with knee osteoarthritis. Results.

International phase III trial of liprotamase efficacy and safety in pancreatic-insufficient cystic fibrosis patients Drucy Borowitz, Christopher Stevens,

Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized,

Coupled microbial and human systems: evidence for a relationship between infectious disease and gross national product T.G. Bromage Clinical Microbiology.

Aimee L. Speck, MD, Michael Hess, MSI, Alan P. Baptist, MD, MPH

Multidomain lifestyle intervention benefits a large elderly population at risk for cognitive decline and dementia regardless of baseline characteristics:

Early decreases in blood eosinophil levels with reslizumab

Effect of patient sex on general anaesthesia and recovery

Antibacterial drug discovery in the 21st century

Profile of Silodosin European Urology Supplements

NICHOLAS J. TALLEY, M.B., Ph.D., SIDNEY F. PHILLIPS, M.D.

Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial Hendrik.

Volume 17, Issue 2, Pages (February 1950)

Evaluation of diagnostic tests

Error processing in patients with Alzheimer's disease

Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial Sonja Ständer, MD, Paul Kwon, MD,

Omalizumab improves asthma-related quality of life in patients with severe allergic asthma Albert Finn, MDa, Gary Gross, MDb, Julius van Bavel, MDc,

High-fidelity patient simulation: validation of performance checklists

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients Eric R. Siemers, Karen L. Sundell, Christopher Carlson, Michael Case,

Clinical effectiveness of laparoscopic fundoplication in a U. S

Multidomain lifestyle intervention benefits a large elderly population at risk for cognitive decline and dementia regardless of baseline characteristics:

A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis Warner Carr, MD, Jonathan Bernstein, MD, Phil Lieberman,

Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal.

Volume 2, Issue 2, Pages (June 2016)

News & Notes Journal of Allergy and Clinical Immunology

CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER.

NICHOLAS J. TALLEY, M.B., Ph.D., SIDNEY F. PHILLIPS, M.D.

Presentation transcript:

Volume 3, Issue 1, Pages 1-9 (January 2017) Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer's disease Juha O. Rinne, Keith Wesnes, Jeffrey L. Cummings, Pasi Hakulinen, Merja Hallikainen, Jutta Hänninen, Michael Murphy, Henry Riordan, Mika Scheinin, Hilkka Soininen, Juha Rouru Alzheimer's & Dementia: Translational Research & Clinical Interventions Volume 3, Issue 1, Pages 1-9 (January 2017) DOI: 10.1016/j.trci.2016.11.004 Copyright © 2016 Orion Pharma Terms and Conditions

Fig. 1 Disposition of subjects. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2017 3, 1-9DOI: (10.1016/j.trci.2016.11.004) Copyright © 2016 Orion Pharma Terms and Conditions

Fig. 2 Quality of Episodic Memory, Quality of Working Memory, and Quality of Memory CDR composite scores. Data are presented as LS means (SE) for changes from baseline. A positive change from baseline indicates improvement. *P < .05, **P < .01, ***P < .001 for difference versus placebo at time point. Abbreviations: CDR, Cognitive Drug Research; LS means, least squares means; SE, standard error. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2017 3, 1-9DOI: (10.1016/j.trci.2016.11.004) Copyright © 2016 Orion Pharma Terms and Conditions

Fig. 3 NPI total and NPI caregiver distress scores. Data are presented as LS means (SE) for changes from baseline. A negative change from baseline indicates improvement. *P < .05, **P < .01 for difference versus placebo at time point. Abbreviations: LS means, least squares means; NPI, Neuropsychiatric Inventory; SE, standard error. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2017 3, 1-9DOI: (10.1016/j.trci.2016.11.004) Copyright © 2016 Orion Pharma Terms and Conditions